Cardiac markers are used in the diagnosis and stratification of risk in patients with chest pain,\u00a0suspected of having an acute coronary syndrome.\u00a0Cardiac troponins, in particular, have become the preferred biomarkers for patients with ACS.<\/p>\n
The use of troponin as a \"gold standard\" biochemical marker has rapidly led to an increase in the number of patients for whom the potential myocardial infarction diagnostic is not real,\u00a0although they exhibit an elevated level of troponin.\u00a0Chronic elevated levels of troponin have been observed in patients with renal impairment.\u00a0Recommendations to use a threshold value for the 99th percentile together with the improved test sensitivity have led to an increase in pathologies associated with elevated levels of troponin.<\/p>\n
The European Cardiology Guide recommends testing patients with high-sensitivity troponin at intake and after three hours or, at intake and after one hour if there are validation studies of the algorithm 0\/1 h.<\/p>\n
Repeated testing allows immediate discrimination between acute and chronic myocardial injury.\u00a0This solves the dilemma of patients with chronic kidney disease or other cardiac pathologies,\u00a0associated with elevated levels of troponin.\u00a0An elevated level of troponin is expected in patients with renal insufficiency.\u00a0A change in troponin concentration indicates an acute injury and may be associated with a myocardial infarction.\u00a0Instead, an increased level of troponin that does not vary over time indicates a chronic condition and requires additional investigations.<\/p>\n
Learn more about the unique Point-of-Care equipment that can determine HS Troponin here<\/span><\/a>.<\/p>\n